Genetic Variants in Pediatric Myeloproliferative Neoplasms Revealed by Next Generation Sequencing

Clinical Laboratory
|July 15, 2025
PubMed
Abstract

Insights

Pediatric myeloproliferative neoplasms (MPNs) show unique genetic profiles. Next-generation sequencing revealed fewer driver mutations in essential thrombocythemia (ET) and multiple non-driver mutations in primary myelofibrosis (PMF) in children.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myeloproliferative neoplasms (MPNs) are rare clonal disorders of hematopoietic stem cells.
  • Pediatric MPNs, including essential thrombocythemia (ET) and primary myelofibrosis (PMF), have limited genetic and biological understanding.
  • Next-generation sequencing (NGS) offers a powerful tool to investigate the genetic landscape of pediatric MPNs.

Purpose of the Study:

  • To identify and characterize genetic variants in pediatric MPNs using NGS.
  • To explore the genetic differences between pediatric and adult MPNs.
  • To assess the clinical significance of identified genetic variants in pediatric MPN patients.

Main Methods:

  • Nine pediatric patients (8 ET, 1 PMF) diagnosed between 2000-2023 were included.
  • Bone marrow aspirate samples were analyzed using next-generation sequencing (NGS) on an Ion S5 XL Sequencer.
  • The OncomineTM myeloid research assay was employed for comprehensive genetic variant detection.

Main Results:

  • Clinically significant genetic variants were identified in 56% of pediatric MPN patients.
  • Two ET patients harbored the JAK2 V617F driver mutation; two others had FLT3 and ETV6 variants.
  • The single PMF patient exhibited 10 variants across eight genes, including novel mutations in BCOR, TET2, and ZRSR2.

Conclusions:

  • Pediatric MPNs present a distinct genetic profile compared to adult forms.
  • Pediatric ET shows a lower incidence of common driver mutations.
  • Pediatric PMF is characterized by multiple non-driver variants, potentially indicating a poorer prognosis.